Table 1. Clinical data of COVID-19 patients according to the age groups.
| Clinical data | 12–19 years (n = 72) | 20–29 years (n = 175) | 30–39 years (n = 127) | 40–49 years (n = 205) | P value | |
|---|---|---|---|---|---|---|
| Sex, male | 35 (48.6) | 82 (46.9) | 60 (47.2) | 95 (46.3) | 0.990 | |
| Underlying disease | ||||||
| Hypertension | 1 (1.4) | 4 (2.3) | 13 (10.2) | 26 (12.7) | < 0.001 | |
| Diabetes | 0 (0.0) | 1 (0.6) | 3 (2.4) | 10 (4.9) | 0.031 | |
| Hyperlipidemia | 0 (0.0) | 2 (1.1) | 7 (5.6) | 19 (9.3) | 0.001 | |
| Chronic lung disease | 4 (5.6) | 11 (6.4) | 6 (4.8) | 8 (3.9) | 0.728 | |
| Cardiovascular disease | 0 (0.0) | 2 (1.1) | 0 (0.0) | 5 (2.4) | 0.243 | |
| Neurovascular disease | 1 (1.4) | 0 (0.0) | 3 (2.4) | 11 (5.4) | 0.005 | |
| Chronic liver disease | 0 (0.0) | 0 (0.0) | 1 (0.8) | 4 (2.0) | 0.236 | |
| Chronic kidney disease | 1 (1.4) | 3 (1.7) | 1 (0.8) | 3 (1.5) | 0.959 | |
| Autoimmune disease | 0 (0.0) | 3 (1.7) | 7 (5.6) | 6 (2.9) | 0.113 | |
| Malignancy | 0 (0.0) | 0 (0.0) | 0 (0.0) | 11 (5.4) | < 0.001 | |
| Laboratory findings | ||||||
| WBC count, ×103 cells/µL | 4.460 (3.748–5.710) | 4.430 (3.717–5.618) | 4.720 (3.650–5.940) | 4.440 (3.465–5.465) | 0.354 | |
| Hemoglobin, g/dL | 13.6 (12.6–14.8) | 13.6 (12.58–14.7) | 13.7 (12.6–14.8) | 13.35 (12.6–14.4) | 0.586 | |
| Platelet, ×103 cells/µL | 214.5 (179.3–252.8) | 211.5 (177.0–245.0) | 208.0 (169.0–260.0) | 206.0 (170.0–243.0) | 0.247 | |
| Absolute neutrophil count, cells/µL | 2,465.2 (1,860–3,573.1) | 2,597.8 (1,880.9–3,516.2) | 2,730.5 (1,872.1–3,749.8) | 2,569.7 (1,820.5–3,531.0) | 0.901 | |
| Absolute lymphocyte count, cells/µL | 1,353.0 (1,069.2–1,684.3) | 1,311.0 (993.8–1,637.7) | 1,343.2 (1,038.2–1,720.6) | 1,228.9 (936.9–1,517.2) | 0.018 | |
| BUN, mg/dL | 12 (10–14) | 12 (10–14) | 12 (10–14) | 12 (10–15.8) | 0.172 | |
| Creatinine, mg/dL | 0.72 (0.59–0.83) | 0.76 (0.61–0.88) | 0.76 (0.64–0.91) | 0.77 (0.63–0.90) | 0.108 | |
| CRP, mg/dL | 0.51 (0.2–1.28) | 0.64 (0.14–1.49) | 0.68 (0.19–1.76) | 0.87 (0.22–1.83) | 0.239 | |
| LDH, U/L | 335.3 (286.9–379.4) | 314.7 (285.1–367.9) | 327.9 (293.9–411.4) | 337.1 (298.2–396.9) | 0.048 | |
| Time duration from last vaccination date to diagnosis, daysa | 70 (38.5–126.0) | 93 (51–127) | 94.5 (44.5–118.5) | 100 (69.3–126) | 0.328 | |
| Duration from symptom onset to hospitalization, daysb | 2.7 (2.3–3.0) | 3.2 (2.9–3.5) | 3.7 (3.3–4.2) | 3.6 (3.2–3.9) | 0.006 | |
| Use of antiviral agents | 1 (1.4) | 10 (5.7) | 15 (11.8) | 26 (12.7) | 0.002 | |
| Use of antibiotics | 25 (34.7) | 27 (15.4) | 20 (15.7) | 42 (20.5) | 0.006 | |
| Oxygen usage | 0 (0.0) | 1 (0.6) | 3 (2.4) | 4 (2.0) | 0.123 | |
| Vaccination status | 0.044 | |||||
| Non-vaccinated | 18 (25.0) | 28 (16.0) | 36 (28.3) | 52 (25.4) | ||
| Incomplete primary vaccine series | 7 (9.7) | 9 (5.1) | 4 (3.1) | 15 (7.3) | ||
| Complete primary vaccine series | 47 (65.3) | 138 (78.9) | 87 (68.5) | 138 (67.3) | ||
Data are presented as the number of patients (%) or median (25th-75th percentiles).
COVID-19 = coronavirus disease 2019, WBC = white blood count, BUN = blood urea nitrogen, CRP = C-reactive protein, LDH = lactate dehydrogenase.
aAmong the 445 vaccinated patients, information about the date of the last vaccination was available for 379.
bPatients with no symptoms (6 patients in their 20s, and 2 patients each in their 30s and 40s) were excluded from the analysis.